Citius Oncology, Inc. Current Assets
Citius Oncology, Inc. (CTOR) had Current Assets of $42.71 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-14
- 2026-06-30: Assets, Current $42.71M.
- 2026-03-31: Assets, Current $29.42M.
- 2025-12-31: Assets, Current $37.15M.
- 2025-09-30: Assets, Current $27.54M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $42.71M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $29.42M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $37.15M 10-Q · filed 2026-02-13 | |
| 2025-09-30 | $27.54M 10-Q · filed 2026-08-14 | |
| 2025-06-30 | $18.31M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $18.04M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $17.08M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $10.97M 10-K · filed 2025-12-23 | |
| 2024-06-30 | $40.99K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $94.39K 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $58.20K 10-Q · filed 2024-08-09 | |
| 2023-09-30 | $7.73M 10-K · filed 2024-12-27 | $85.16K 10-Q · filed 2023-11-20 |
| 2023-06-30 | $461.91K 10-Q · filed 2023-08-16 | |
| 2023-03-31 | $245.37K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $377.34K 10-K · filed 2024-04-16 | |
| 2021-12-31 | $126.42K 10-K · filed 2023-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |